 Dr Lal PathLabs Limited declares 2nd interim dividend of Rs. 7
Dr Lal PathLabs Limited declares 2nd interim dividend of Rs. 7 Dwarikesh Sugar Industries Ltd Q2FY26 loss at Rs. 32.62 crores
Dwarikesh Sugar Industries Ltd Q2FY26 loss at Rs. 32.62 crores Nitta Gelatin India Ltd Q2 FY2025-26 consolidated profit lower at Rs. 18.42 crores
Nitta Gelatin India Ltd Q2 FY2025-26 consolidated profit lower at Rs. 18.42 crores Wheels India Ltd consolidated Q2 FY26 net profit up at Rs. 30.99 crores
Wheels India Ltd consolidated Q2 FY26 net profit up at Rs. 30.99 crores Kalpataru Projects International Ltd posts rise in Q2FY26 consolidated PAT to Rs. 240.05 crores
Kalpataru Projects International Ltd posts rise in Q2FY26 consolidated PAT to Rs. 240.05 crores 
              Sharon Bio Medicine Ltd has announced that has announced that the members at the Extra Ordinary General Meeting (EGM) of the Company held on March 15, 2007, inter alia, have accorded to the following & the Board of Directors has been authorized for:
1. Issue of FCCBs for an amount not exceeding Rs 200 crores.
2. Preferential allotment of 1,50,000 equity shares to M/s Pharmtak Ltd, Mauritius at a Price of Rs 300/- per share.
3. Preferential allotment of 3,75,000 warrants to M/s Asis Industries Ltd at a price of Rs 300/- per warrant.
4. Issue of Equity shares or Convertible instruments to Qualified Institutional Buyers (QIBs) for an amount not exceeding Rs 200 crore.